1-Boc-4-(6-氨基嘧啶-4-基)哌嗪 | 436851-80-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-Boc-4-(6-氨基嘧啶-4-基)哌嗪
• 英文名称: tert-butyl 4-(6-aminopyrimidin-4-yl)piperazine-1-carboxylate
• CAS: 436851-80-8
• 化学式: C₁₃H₂₁N₅O₂
• mdl: MFCD11109805
• 分子量: 279.342
• InChiKey: JOZCBLMCQBMONN-UHFFFAOYSA-N

物化性质

• 沸点：
  472.3±45.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.615
• 拓扑面积：
  84.6
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  1-Boc-4-(6-氨基嘧啶-4-基)哌嗪 在 N-溴代丁二酰亚胺(NBS) 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 8.0h， 生成 5-bromo-6-(piperazin-1-yl)pyrimidin-4-amine
  参考文献：
  名称：

  Integrating docking scores, interaction profiles and molecular descriptors to improve the accuracy of molecular docking: Toward the discovery of novel Akt1 inhibitors

  摘要：

  A set of forty-seven Akt1 inhibitors was used for the development of molecular docking based QSAR model by using nonlinear regression. The integration of docking scores, key interaction profiles and molecular descriptors remarkably improved the accuracy of the QSAR models, providing reasonable statistical parameters (R-train(2) = 0.948, R-test(2) = 0.907 and Q(cv)(2) = 0.794). The established MD-SVR model based structural modification of new 4-amino-pyrimidine derivatives was further performed, and six compounds 56a,b and 60a-d with good prediction activities were synthesized and biologically evaluated. All of these compounds exhibited promising Akt1 inhibitory and antiproliferative activities, suggesting the reliability and good application value of the established MD-SVR model in the development of Akt1 inhibitors. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.01.019
• 作为产物：
  描述：

  4-氨基-6-氯嘧啶 、 N-Boc-哌嗪 以 甲苯 为溶剂， 反应 24.0h， 以67%的产率得到1-Boc-4-(6-氨基嘧啶-4-基)哌嗪
  参考文献：
  名称：

  吡啶酮-氨基衍生物作为MNK1 / 2抑制剂的设计，合成和生物学评估。

  摘要：

  真核翻译起始因子4E（eIF4E）的过度磷酸化在mRNA翻译失调和肿瘤细胞信号激活中起主要作用。eIF4E仅被Ser209上的促分裂原活化蛋白激酶相互作用的激酶1和2（MNK1 / 2）磷酸化。因此，MNK1 / 2抑制剂可以降低p-eIF4E的水平并调节肿瘤相关的信号通路。合成了一系列吡啶酮-氨基衍生物，并作为MNK1 / 2抑制剂进行了评估。几种化合物对MNK1 / 2表现出极大的抑制活性，某些化合物对血液癌细胞系表现出中度至优异的抗增殖能力。特别地，化合物42i（MNK1 IC50 = 7.0 nM； MNK2 IC50 = 6.1 nM）被证明是针对TMD-8细胞系最有效的化合物，IC50值为0.91μM。此外，42i可以阻断CT-26细胞系中eIF4E的磷酸化水平，42i可以显着抑制CT-26同种异体移植模型的肿瘤生长。这些结果表明，化合物42i是有效治疗结肠癌的有希望的MNK1

  DOI：

  10.1016/j.bmc.2019.02.007

文献信息

• [EN] BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2<br/>[FR] COMPOSÉ BICYCLIQUE ET SON UTILISATION POUR INHIBER SUV39H2
  申请人：ONCOTHERAPY SCIENCE INC

  公开号：WO2017058503A1

  公开（公告）日：2017-04-06

  The present invention directs to a compound represented by formula (I).

  本发明涉及一种由化学式（I）表示的化合物。
• Tyrosine kinase inhibitors
  申请人：——

  公开号：US20020137755A1

  公开（公告）日：2002-09-26

  The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

  本发明涉及抑制、调节和/或调控酪氨酸激酶信号传导的化合物，含有这些化合物的组合物，以及使用它们治疗依赖于酪氨酸激酶的疾病和病况的方法，如在哺乳动物中的血管生成、癌症、肿瘤生长、动脉粥样硬化、老年性黄斑变性、糖尿病视网膜病变、炎症性疾病等。
• BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2
  申请人：OncoTherapy Science, Inc.

  公开号：EP3355699B1

  公开（公告）日：2021-03-31
• Integrating docking scores, interaction profiles and molecular descriptors to improve the accuracy of molecular docking: Toward the discovery of novel Akt1 inhibitors
  作者：Wenhu Zhan、Daqiang Li、Jinxin Che、Liangren Zhang、Bo Yang、Yongzhou Hu、Tao Liu、Xiaowu Dong

  DOI：10.1016/j.ejmech.2014.01.019

  日期：2014.3

  A set of forty-seven Akt1 inhibitors was used for the development of molecular docking based QSAR model by using nonlinear regression. The integration of docking scores, key interaction profiles and molecular descriptors remarkably improved the accuracy of the QSAR models, providing reasonable statistical parameters (R-train(2) = 0.948, R-test(2) = 0.907 and Q(cv)(2) = 0.794). The established MD-SVR model based structural modification of new 4-amino-pyrimidine derivatives was further performed, and six compounds 56a,b and 60a-d with good prediction activities were synthesized and biologically evaluated. All of these compounds exhibited promising Akt1 inhibitory and antiproliferative activities, suggesting the reliability and good application value of the established MD-SVR model in the development of Akt1 inhibitors. (C) 2014 Elsevier Masson SAS. All rights reserved.
• Design, synthesis and biological evaluation of pyridone–aminal derivatives as MNK1/2 inhibitors
  作者：Xinrui Yuan、Hanshu Wu、Hong Bu、Peiyuan Zheng、Jinpei Zhou、Huibin Zhang

  DOI：10.1016/j.bmc.2019.02.007

  日期：2019.4

  phosphorylated by mitogen-activated protein kinase interacting kinases 1 and 2 (MNK1/2) on Ser209. So, MNK1/2 inhibitors could decrease the level of p-eIF4E and regulate tumor-associated signaling pathways. A series of pyridone-aminal derivatives were synthesized and evaluated as MNK1/2 inhibitors. Several compounds exhibited great inhibitory activity against MNK1/2 and selected compounds showed moderate

  真核翻译起始因子4E（eIF4E）的过度磷酸化在mRNA翻译失调和肿瘤细胞信号激活中起主要作用。eIF4E仅被Ser209上的促分裂原活化蛋白激酶相互作用的激酶1和2（MNK1 / 2）磷酸化。因此，MNK1 / 2抑制剂可以降低p-eIF4E的水平并调节肿瘤相关的信号通路。合成了一系列吡啶酮-氨基衍生物，并作为MNK1 / 2抑制剂进行了评估。几种化合物对MNK1 / 2表现出极大的抑制活性，某些化合物对血液癌细胞系表现出中度至优异的抗增殖能力。特别地，化合物42i（MNK1 IC50 = 7.0 nM； MNK2 IC50 = 6.1 nM）被证明是针对TMD-8细胞系最有效的化合物，IC50值为0.91μM。此外，42i可以阻断CT-26细胞系中eIF4E的磷酸化水平，42i可以显着抑制CT-26同种异体移植模型的肿瘤生长。这些结果表明，化合物42i是有效治疗结肠癌的有希望的MNK1